BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21622196)

  • 1. Role of purinergic receptor polymorphisms in human bone.
    Wesselius A; Bours MJ; Agrawal A; Gartland A; Dagnelie PC; Schwarz P; Jorgensen NR
    Front Biosci (Landmark Ed); 2011 Jun; 16(7):2572-85. PubMed ID: 21622196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-affinity P2Y2 and low-affinity P2X7 receptor interaction modulates ATP-mediated calcium signaling in murine osteoblasts.
    Mikolajewicz N; Smith D; Komarova SV; Khadra A
    PLoS Comput Biol; 2021 Jun; 17(6):e1008872. PubMed ID: 34153025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2 receptors in bone--modulation of osteoclast formation and activity via P2X7 activation.
    Gartland A; Buckley KA; Hipskind RA; Bowler WB; Gallagher JA
    Crit Rev Eukaryot Gene Expr; 2003; 13(2-4):237-42. PubMed ID: 14696970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATP P2 receptors and regulation of bone effector cells.
    Gallagher JA
    J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):125-7. PubMed ID: 15615109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of a P2X7 receptor by a subpopulation of human osteoblasts.
    Gartland A; Hipskind RA; Gallagher JA; Bowler WB
    J Bone Miner Res; 2001 May; 16(5):846-56. PubMed ID: 11341329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular nucleotides act through P2X7 receptors to activate NF-kappaB in osteoclasts.
    Korcok J; Raimundo LN; Ke HZ; Sims SM; Dixon SJ
    J Bone Miner Res; 2004 Apr; 19(4):642-51. PubMed ID: 15005852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of P2 receptors in bone and cultured bone cells.
    Hoebertz A; Townsend-Nicholson A; Glass R; Burnstock G; Arnett TR
    Bone; 2000 Oct; 27(4):503-10. PubMed ID: 11033445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the P2Y
    Orriss IR; Guneri D; Hajjawi MOR; Shaw K; Patel JJ; Arnett TR
    J Endocrinol; 2017 Jun; 233(3):341-356. PubMed ID: 28420708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The purinergic P2X7 ion channel receptor-a 'repair' receptor in bone.
    Jørgensen NR
    Curr Opin Immunol; 2018 Jun; 52():32-38. PubMed ID: 29587220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts.
    Korcok J; Raimundo LN; Du X; Sims SM; Dixon SJ
    J Biol Chem; 2005 Apr; 280(17):16909-15. PubMed ID: 15722352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [P2 purinergic receptors: regulation of bone metabolism and therapeutic potential?].
    Solgaard M; Jørgensen NR
    Ugeskr Laeger; 2005 Aug; 167(34):3152-6. PubMed ID: 16117911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2Y2 receptors are expressed by human osteoclasts of giant cell tumor but do not mediate ATP-induced bone resorption.
    Bowler WB; Littlewood-Evans A; Bilbe G; Gallagher JA; Dixon CJ
    Bone; 1998 Mar; 22(3):195-200. PubMed ID: 9514211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone phenotypes of P2 receptor knockout mice.
    Orriss I; Syberg S; Wang N; Robaye B; Gartland A; Jorgensen N; Arnett T; Boeynaems JM
    Front Biosci (Schol Ed); 2011 Jun; 3(3):1038-46. PubMed ID: 21622253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced bone turnover in mice lacking the P2Y13 receptor of ADP.
    Wang N; Robaye B; Agrawal A; Skerry TM; Boeynaems JM; Gartland A
    Mol Endocrinol; 2012 Jan; 26(1):142-52. PubMed ID: 22108801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purinergic signalling in osteoblasts.
    Gartland A; Orriss IR; Rumney RM; Bond AP; Arnett T; Gallagher JA
    Front Biosci (Landmark Ed); 2012 Jan; 17(1):16-29. PubMed ID: 22201729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular nucleotide signaling: a mechanism for integrating local and systemic responses in the activation of bone remodeling.
    Bowler WB; Buckley KA; Gartland A; Hipskind RA; Bilbe G; Gallagher JA
    Bone; 2001 May; 28(5):507-12. PubMed ID: 11344050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purinergic signaling in kidney disease.
    Menzies RI; Tam FW; Unwin RJ; Bailey MA
    Kidney Int; 2017 Feb; 91(2):315-323. PubMed ID: 27780585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2 Receptors in Cardiac Myocyte Pathophysiology and Mechanotransduction.
    Woo SH; Trinh TN
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The regulation of osteoblast function and bone mineralisation by extracellular nucleotides: The role of p2x receptors.
    Orriss IR; Key ML; Brandao-Burch A; Patel JJ; Burnstock G; Arnett TR
    Bone; 2012 Sep; 51(3):389-400. PubMed ID: 22749889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purinergic signalling and bone remodelling.
    Orriss IR; Burnstock G; Arnett TR
    Curr Opin Pharmacol; 2010 Jun; 10(3):322-30. PubMed ID: 20189453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.